Tranilast administration reduces fibrosis and improves fatigue resistance in muscles of mdx dystrophic mice by Kristy Swiderski et al.
Swiderski et al. Fibrogenesis & Tissue Repair 2014, 7:1
http://www.fibrogenesis.com/content/7/1/1RESEARCH Open AccessTranilast administration reduces fibrosis and
improves fatigue resistance in muscles of mdx
dystrophic mice
Kristy Swiderski, Michelle Todorov, Stefan M Gehrig, Timur Naim, Annabel Chee, David I Stapleton,
René Koopman and Gordon S Lynch*Abstract
Background: Duchenne muscular dystrophy (DMD) is a severe and progressive muscle-wasting disorder caused by
mutations in the dystrophin gene that result in the absence of the membrane-stabilising protein dystrophin.
Dystrophic muscle fibres are susceptible to injury and degeneration, and impaired muscle regeneration is associated
with fibrotic deposition that limits the efficacy of potential pharmacological, cell- and gene-based therapies. Novel
treatments that can prevent or attenuate fibrosis have important clinical merit for DMD and related neuromuscular
diseases. We investigated the therapeutic potential for tranilast, an orally bioavailable anti-allergic agent, to prevent
fibrosis in skeletal muscles of mdx dystrophic mice.
Results: Three-week-old C57Bl/10 and mdx mice received tranilast (~300 mg/kg) in their food for 9 weeks, after
which fibrosis was assessed through histological analyses, and functional properties of tibialis anterior muscles were
assessed in situ and diaphragm muscle strips in vitro. Tranilast administration did not significantly alter the mass of
any muscles in control or mdx mice, but it decreased fibrosis in the severely affected diaphragm muscle by 31%
compared with untreated mdx mice (P < 0.05). A similar trend of decreased fibrosis was observed in the tibialis
anterior muscles of mdx mice (P = 0.10). These reductions in fibrotic deposition were not associated with
improvements in maximum force-producing capacity, but we did observe small but significant improvements in
the resistance to fatigue in both the diaphragm and TA muscles of mdx mice treated with tranilast.
Conclusion: Together these findings demonstrate that administration of potent antifibrotic compounds such as
tranilast could help preserve skeletal muscle structure, which could ultimately increase the efficacy of
pharmacological, cell and gene replacement/correction therapies for muscular dystrophy and related disorders.Background
Duchenne muscular dystrophy (DMD) is a severe, X-
linked genetic muscle-wasting disorder characterised by
progressive muscle weakness that culminates in respira-
tory failure and premature death. The disease affects
approximately 1:3,500 live male births worldwide, and
affected boys are usually wheelchair bound by their early
teens and experience a severely reduced quality of life.
DMD is caused by mutations in the dystrophin (dmd)
gene resulting in very low levels or a complete absence
of the dystrophin protein, a key structural element of
muscle fibres that renders them highly susceptible to* Correspondence: gsl@unimelb.edu.au
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reproduction in any medium, provided the ordamage. As a consequence, dystrophic muscles are char-
acterised by inflammation and ongoing cycles of degener-
ation and regeneration. This environment limits muscle
regenerative capacity and there is concomitant replace-
ment of formerly functional muscle fibres with adipose
and fibrotic material (reviewed in [1]).
The mdx mouse is the most commonly used animal
model of DMD. It arose from a natural mutation in a
colony of C57BL/10 mice in which a premature stop
codon was introduced into the dmd gene, resulting in a
complete loss of the dystrophin protein [2,3]. While this
model is a good genocopy of the human disease, the
pathology of the mdx mouse does not mimic that ob-
served in DMD. Mdx mice exhibit a mild pathology with
a slightly reduced lifespan (18–24 months) and functionalal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mately 18 months of age [4], which is most likely a result
of modifier genes in the C57BL/10 strain that can alter the
effect of dystrophin loss on skeletal muscle pathology.
Unlike the hindlimb muscles, the diaphragm of mdx mice
undergoes progressive deterioration of muscle structure
and function and is therefore a preferred muscle when
examining the efficacy of potential therapeutic agents of
clinical relevance [5-7].
As DMD is caused by mutations in a single gene, one
of the most promising therapies is through gene replace-
ment. However, while gene replacement or correction
studies are likely to provide an eventual cure for DMD,
several barriers need to be overcome including the presence
of fibrosis within dystrophic skeletal muscles (reviewed in
[8]). Fibrosis not only creates a physical barrier, but also
replaces the muscle fibres that can be targeted, limiting
the efficacy of cell- and gene-based therapies. Attenuating
fibrotic infiltration may be needed to optimise gene, cell
and pharmacological therapies.
Various agents with antifibrotic properties have been
trialled to reduce fibrosis deposition in skeletal muscle.
Suramin, a TGF-β inhibitor, and interleukin-15 (IL-15)
have been shown to reduce muscle fibrosis but can have
side effects when administered systemically [9-11]. An-
other compound with antifibrotic properties is trani-
last, an orally bioavailable antiallergic agent that has
been approved for use in the human population in
Japan and South Korea since 1982 for the treatment
of bronchial asthma, atopic dermatitis and allergic rhin-
itis [12-17]. Since that time, the effectiveness of tranilast
as a therapeutic agent for a range of fibrotic disorders
and its mechanism of action have been studied exten-
sively both in vitro and in vivo (reviewed in [18]). In
1992, Suzawa and colleagues [19] demonstrated that
tranilast suppressed release of profibrotic cytokines from
monocyte-macrophages in vitro [19], highlighting trani-
last’s antifibrotic properties. Tranilast has subsequently
been demonstrated to reduce tuberointerstitial and
heart fibrosis in diabetic rat models and to block
TGF-β-induced fibrosis in vitro and in vivo [20-24].
In addition, tranilast administration was found to be
efficacious in reducing muscle fibrosis in the Bio14.6
hamster model of limb-girdle muscular dystrophy and
reducing serum creatine kinase levels in mdx dys-
trophic mice, effects they suggest may be a result of
tranilast-mediated inhibition of the Ca2+-permeable
growth factor-regulated channel (TRPV2 or GRC)
[18,25]. In this study, we report that short-term ad-
ministration of tranilast in mdx mice decreases fibro-
sis in skeletal muscle and improves the resistance to
muscle fatigue. Together these findings demonstrate
that tranilast has therapeutic potential to combat fi-
brosis in muscle diseases such as DMD.Results
Tranilast does not alter skeletal muscle mass or strength
At the end of the 9-week treatment period, the tibialis
anterior (TA), soleus (SOL), extensor digitorum longus
(EDL), plantaris (PLANT), gastrocnemius (GAST), quad-
riceps (QUAD) and heart muscles from both non-treated
and treated mdx mice were significantly larger than those
from non-treated and treated control mice (Figure 1A).
These differences cannot be attributed to differences in
food intake as daily intake was not different between
strains or treatment groups (data not shown) and averaged
3.3 g/mouse/day. Administration of tranilast did not sig-
nificantly alter the mass of any of the tested skeletal
muscles in control or mdx mice (Figure 1A). Conse-
quently, 9-week treatment with tranilast did not affect
whole-body strength (Figure 1B) or mobility (Figure 1C),
as assessed by grip strength and rotarod performance.
Fibrotic deposition is decreased in muscles of
tranilast-treated dystrophic mice
The TA and diaphragm muscles of mdx mice contained
three- and nine-fold more fibrosis, respectively, com-
pared with control mice (Figure 2). Tranilast administration
to young mdx mice for 9 weeks resulted in a significant
three-fold (31%) decrease in fibrosis in the diaphragm com-
pared with untreated mdx mice (Figure 2A-C, P < 0.05).
A similar trend (30% decrease, P = 0.10) was observed
in the TA muscles of mdx mice. The level of fibrosis
in the TA muscles and diaphragm of control animals was
naturally very low and unchanged with tranilast adminis-
tration (Figure 2C). Analysis of gene expression revealed
that Collagen 1a1, 3a1, 5a1 and TGFβ genes were all more
highly expressed in the diaphragm of mdx compared to
C57BL/10 mice, but tranilast treatment had no effect on
the expression levels of these genes (Table 1). Tranilast
treatment resulted in a change in fibre type distribution in
the TA muscles of mdx mice with an increased proportion
of type IIa fibres with a concomitant decrease in type IIb/
x fibres compared with muscles from untreated mdx mice
(Table 2). No significant differences were observed be-
tween tranilast-treated and control mdx mice in fibre
cross-sectional area or oxidative enzyme capacity in either
the TA or diaphragm muscles (Table 2).
Tranilast administration improves resistance to muscle
fatigue in dystrophic mice
Dystrophic mdx mice exhibited a ~40% reduction in
diaphragm- and TA-specific force compared with con-
trol (Figure 3A/B). Nine-week treatment with tranilast
did not improve whole-body strength or mobility and
did not improve maximum force-producing capacity in
the TA or diaphragm muscles of control or mdx mice
(i.e., for TA muscle: C57BL/10 control 1,825 ± 35 mN
vs. C57Bl/10 tranilast 1,743 ± 55 mN; mdx control
Figure 1 Tranilast effects on muscle mass and whole body strength of mdx mice. Three-week-old male C57Bl/10 control mice or mdx mice
received either vehicle or tranilast treatment for 9 weeks. (A) Individual muscle masses at the end of the treatment period. (B) Grip strength was
measured 3 days prior to endpoint. (C) Whole body function and coordination was assessed by rotarod performance 2 days prior to endpoint.
QUAD: quadriceps; GAST: gastrocnemius; TA: tibialis anterior; PLANT: plantaris; EDL: extensor digitorum longus; SOL: soleus. #P < 0.05 group main
effect, mdx vs. control.
Figure 2 Tranilast effects on fibrosis in the diaphragm and TA of mdx mice. At endpoint, the diaphragm muscle of vehicle-treated C57BL/
10 (A), vehicle-treated mdx (B), tranilast-treated C57BL/10 (C) or tranilast-treated mdx (D) mice was excised and collagen infiltration visualised in
cross-sections after Van Gieson’s staining. (E) Fibrotic accumulation in Van Gieson’s stained sections from diaphragm and tibialis anterior muscles
of untreated and treated mice. #P < 0.05 group main effect, mdx vs. control. *P < 0.05 mdx treated vs. mdx control; n.s, not significant.
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Table 1 Tranilast administration does not cause a
long-term change in fibrotic gene expression in the
diaphragm
CON + VEH CON + TRA mdx-VEH mdx-TRA
Col1a1 1.00±0.09 0.83±0.13 3.42±0.42* 3.37±0.33*
Col2a1 1.00±0.28 1.23±0.47 0.79±0.20 0.92±0.34
Col3a1 1.00±0.10 0.89±0.13 3.72±0.26* 3.27±0.34*
Col4a1 1.00±0.06 0.87±0.11 1.31±0.14 1.35±0.13
Col5a1 1.00±0.09 0.91±0.08 3.46±0.24* 3.40±0.36*
COl6a1 1.00±0.06 0.87±0.11 1.31±0.14 1.35±0.13
Fn1 1.00±0.14 1.34±0.07 1.00±0.14 1.01±0.18
TGFβ1 1.00±0.11 0.86±0.07 1.48±0.04* 1.45±0.12*
At the conclusion of the treatment period RNA was extracted and real-time
PCR analysis was used to examine the expression level of genes known to be
associated with fibrosis. *P < 0.05 mdx vs. control.
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However, force production during a 4-min fatiguing
stimulation protocol was improved in both the dia-
phragm and TA muscles of tranilast-treated mdx mice
(Figure 3B, C).
Tranilast impairs glucose tolerance in control and
dystrophic mice
To check whether tranilast administration altered glu-
cose handling in control and dystrophic mice we also
performed a glucose tolerance test. Dystrophic mdx
mice exhibited impaired glucose tolerance as evidenced
by a 100% higher glucose response following a single in-
traperitoneal injection of glucose (1 g/kg) (expressed as
area under the curve, Figure 4, p < 0.05). While basal
blood glucose levels were not affected by tranilast ad-
ministration, ~20% increased peak blood glucose levels
were observed in treated control and mdx mice com-
pared with untreated mice during the GTT (Figure 4).
Furthermore, the blood glucose response was ~70%
higher in tranilast-treated control and mdx mice com-
pared with untreated mice (Figure 4).Table 2 Tranilast administration causes a shift in fibre type p
CON + VEH CON
Tibialis anterior
Fibre CSA (μm2) 1,811.4 ± 54.9 1,859
SDH intensity (o.d.) 1,645.4 ± 57.4 1,622
% Type IIa fibres 11.0 ± 3.1 9.1 ±
Diaphragm
Fibre CSA (μm2) 1,010.6 ± 69.3 949.8
SDH intensity (o.d.) 2,004.0 ± 63.9 1,725
% Type IIa fibres 63.8 ± 1.6 67.8 ±
At the conclusion of the treatment period the fibre cross-sectional area (CSA), fibre
of cross-sections stained with H&E and reacted for succinate dehydrogenase (S
vehicle-treated mdx mice.Discussion
The identification of pharmacological agents that can
prevent, reduce and/or resolve fibrotic deposition has
great potential for enhancing therapies for DMD and
other muscle-wasting disorders. While gene and cell
therapies will eventually provide the cure for the single-
gene muscle-wasting disorders, the efficacy of these
approaches is likely to be hampered by the presence of
significant fibrosis within affected skeletal muscles. Here
we have demonstrated that one agent, tranilast, success-
fully reduces fibrotic deposition in skeletal muscles of
mdx dystrophic mice.
Tranilast has been administered to sarcoglycan-deficient
Bio14.6 hamsters, a rodent model of limb-girdle muscular
dystrophy (LGMD). Treatment of 30-day-old hamsters for
120 days significantly decreased fibrosis in skeletal muscle
and reduced serum creatine kinase levels and the number
of centrally nucleated muscle fibres, indicating reduced
muscle fibre breakdown and regeneration [25]. That study
also observed a reduction in serum creatine kinase levels
after a 30-day treatment in 30-day-old mdx mice [25]. We
have subsequently demonstrated that oral administration
of tranilast (~300 mg/kg) to young mice for 9 weeks sig-
nificantly reduced fibrotic accumulation by ~30% in the
diaphragm muscles of mdx mice (Figure 2A, B, C). We
observed a similar trend towards a decrease in fibrosis ac-
cumulation in the TA muscles of treated mdx mice but
this was not statistically significant (P = 0.10). This is most
likely due to the low levels of fibrosis in the TA muscles
compared with those in the diaphragm of mdx mice. The
observed decrease in the diaphragm, which is the most se-
verely affected of the muscles in the mdx mouse, indicates
that tranilast was able to reduce fibrotic accumulation.
We did not observe a change in the maximum force pro-
duction of the TA muscle or diaphragm muscle strips,
which is not surprising since a 30% reduction in fibrosis in
these muscles of mdx mice would only increase the avail-
able functional tissue in the TA and diaphragm by 1.5%
and 5%, respectively. We did not observe an improvementroportions in the TA muscles of mdx mice
+ TRA mdx + VEH mdx + TRA
.7 ± 74.3 1,890.2 ± 54.0 1,932.2 ± 113.6
.3 ± 36.6 1,497.2 ± 74.1† 1,464.7 ± 48.9†
1.6 4.9 ± 0.6 10.8 ± 0.5*
± 69.8 764.9 ± 39.9† 874.6 ± 65.3†
.6 ± 212.3 1,897.3 ± 46.2† 1,793.1 ± 124.1†
3.9 71.5 ± 2.6† 78.6 ± 3.3†
type and oxidative enzyme activity were determined by histological evaluations
DH) activity. †P < 0.05, group main effect; *P < 0.05, tranilast-treated vs.
Figure 3 Tranilast effects on fatigue of diaphragm muscle strips and tibialis anterior muscles of mdx mice. Analysis of the frequency-force
relationship showed significant reductions in specific force in the mdx TA and diaphragm compared to controls, which was not altered with
administration of tranilast (A/B). At the conclusion of treatment, resistance to fatigue was determined from intermittent stimulation of
(C) diaphragm muscle strips evaluated in vitro or (D) TA muscles evaluated in situ, from vehicle or tranilast-treated mdx mice. Values are expressed as
relative specific force (force per cross-sectional area) during the 4-min stimulation protocol. #P < 0.05 group main effect, mdx vs. control. *P < 0.05
treatment main effect.
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in maximum force of diaphragm muscle strips. Other
compounds with specific muscle effects and antifibrotic
properties such as IL-15 and sildenafil have been shown
to improve the muscle force-producing capacity [26,27].Figure 4 Tranilast treatment effects on glucose tolerance in mdx mice.
control and mdx mice during the final week of treatment. Changes in
calculated glucose response (B; area under the curve). #P < 0.05 group main eHowever, we did observe an improvement in the fatigabil-
ity of both the diaphragm and TA muscles in treated mdx
mice, indicating a potential improvement in muscle func-
tion. This improved fatigue resistance was not due to any
changes in the muscle oxidative capacity, as there were noGlucose tolerance tests were performed on vehicle and tranilast-treated
blood glucose over time during the glucose tolerance test (A) and
ffect, mdx vs. control. *P < 0.05 treatment main effect.
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tween control and tranilast-treated mice (Table 1).
Although tranilast administration successfully de-
creased fibrotic tissue infiltration in dystrophic skeletal
muscle, one concern was that it also resulted in impaired
glucose tolerance in both dystrophic and control mice.
Tranilast has been shown to inhibit insulin secretion in
rats [28], so long-term treatment may not be possible
using this specific compound. However, the effective hu-
man dose of tranilast for fibrotic pathology has been
shown to be 5 mg/kg, and subsequent safety information
regarding the use of tranilast in humans at this dose has
not indicated toxicity issues associated with effects on in-
sulin secretion [18]. It remains to be determined whether
this dose, which is significantly lower than the dose used
in the present study, would be sufficient to alter fibrosis in
human skeletal muscle. Therefore it is possible that newer
generation drugs may be required for therapeutic applica-
tion. To this end, more targeted drugs based on the struc-
ture of tranilast are being developed that can attenuate
interstitial fibrosis in the hearts of diabetic rats without
causing hyperglycaemia [29].
Conclusion
Interventions to minimise fibrosis are important not just
for skeletal muscle diseases but also to enhance func-
tional recovery after serious muscle injuries. Although
tranilast decreased fibrosis in dystrophic skeletal mus-
cles, functional benefits were limited to modest improve-
ments in fatigue resistance with impaired glucose
tolerance also being a limiting factor. These issues need
to be overcome in order to improve the therapeutic rele-
vance and efficacy. Together these findings demonstrate
that administration of potent antifibrotic compounds
such as tranilast and newer drugs could help preserve
skeletal muscle structure to ultimately increase the effi-
cacy of pharmacological, cell and gene replacement/




Three-week-old male C57BL/10 (n = 32) and C57BL/
10ScSn mdx (mdx) (n = 32) mice were obtained from
the Animal Resources Centre (ARC), WA, Australia. All
experimental protocols were approved by the Animal
Ethics Committee of The University of Melbourne and
conducted in accordance with the Australian code of prac-
tice for the care and use of animals for scientific purposes
as stipulated by the National Health and Medical Research
Council (Australia).
Mice were allocated into one of four groups: (1) control
group treated with vehicle (CON+VEH, n = 16); (2) con-
trol group treated with tranilast (CON + TRA, n = 16);(3) mdx group treated with vehicle (mdx + VEH, n = 16);
(4) mdx group treated with tranilast (mdx + TRA, n = 16).
Tranilast administration
Three-week-old control (C57BL/10) and mdx mice re-
ceived tranilast (kindly provided by Dr. Spencer Williams,
Department of Chemistry, The University of Melbourne)
for a period of 9 weeks. Mice received standard laboratory
chow (Speciality Feeds, Glen Forrest, WA, Australia) with
or without the addition of 2.7 g tranilast/kg. Food was
made available ad libitum based on the assumption that
mice would consume approximately 4 g of feed per day
resulting in a dose of 400 mg/kg/day of tranilast. This dose
has been shown previously to reduce collagen infiltration
in heart [20] and kidney [30] of diabetic rats. Food intake
was monitored throughout the treatment period [20] and
as mice consumed an average 3.3 g/day, daily tranilast in-
take averaged 293 mg/day.
Measurement of whole body strength
Whole body strength, whole body mobility and coordination
were assessed in control C57BL/10, treated C57BL/10,
control mdx and treated mdx mice at 2 (mobility) or 3
(body strength) days prior to endpoint by means of a grip
strength meter (Columbus Instruments, Columbus, OH)
and rotarod performance test (Rotamex-5, Columbus
Instruments) as described previously [31].
Glucose tolerance test
Glucose tolerance tests were performed on control C57BL/
10, treated C57BL/10, control mdx and treated mdx mice 5
days prior to endpoint. Following an overnight fast, a basal
blood sample was taken from the tail vein (23 G needle)
and analysed for glucose concentration using a glucometer.
Mice then received an intraperitoneal injection of glucose
solution (1 g/kg body mass). At 15, 30, 60, 90 and 120 min
after the injection of the glucose solution, a blood sample
was collected from the tail vein (23 G needle) and analysed
for glucose concentration.
Assessment of contractile properties of skeletal muscle
and tissue collection
At the conclusion of the treatment period, mice were
anesthetised with sodium pentobarbitone (Nembutal;
60 mg/kg; Sigma-Aldrich) via i.p. injection. The methods
for assessment of the contractile properties of the mouse
tibialis anterior (TA) muscle in situ have been described in
detail previously [32]. At the conclusion of the contractile
measurements in situ, the TA muscle was carefully ex-
cised, blotted on filter paper and weighed on an analytical
balance, followed by freezing in thawing isopentane for
later histological examination. Soleus (SOL), extensor digi-
torum longus (EDL), plantaris (PLAN), gastrocnemius
(GAST) and quadriceps (QUAD) muscles were excised,
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hering tissue, weighed and frozen in liquid nitrogen.
The entire diaphragm and rib cage were then surgically
excised and costal diaphragm muscle strips composed of
longitudinally arranged full-length muscle fibres were iso-
lated and prepared for functional assessment in vitro, as
described in detail elsewhere [32]. Upon completion of the
functional analyses, the diaphragm muscle strip was
trimmed of tendon and any adhering non-muscle tissue,
blotted once on filter paper and weighed on an analytical
balance. The muscle strips were then frozen in thawing
isopentane for later histological examination. Mice were
killed as a consequence of diaphragm and heart excision
while deeply anesthetised.
Skeletal muscle histology and fibrosis
Serial sections (5 μm) were cut transversely through the
diaphragm and the TA muscle using a refrigerated (−20°C)
cryostat (CTI Cryostat; IEC, Needham Heights, MA). Sec-
tions were stained with haematoxylin and eosin (H&E)
to reveal the general muscle architecture. Muscle fibre
cross-sectional area, oxidative enzyme capacity and fibre
type were determined as described previously [33]. Briefly,
TA and diaphragm sections were reacted histochemically
for succinate dehydrogenase (SDH) activity and immunor-
eacted with antibodies to laminin (Sigma-Aldrich) and
myosin IIa, N2.261 (The University of Iowa, Department
of Biology, Iowa City, IA; USA) in order to determine
the oxidative capacity, CSA of individual myofibers
and proportion of type IIA fibres respectively. Muscle
collagen content was assessed from Van Gieson-stained
cross-sections [32]. Digital images of stained sections were
obtained using an upright microscope with a camera
(Axio Imager D1, Carl Zeiss, Wrek, Göttingen, Germany),
controlled by AxioVision AC software (AxioVision AC
Rel. 4.8, Carl Zeiss Imaging Solutions, Wrek, Göttingen,
Germany). Images were quantified using AxioVision 4.8
software.
Analysis of gene expression
At the conclusion of the treatment period, diaphragm
muscles were excised and total RNA was extracted using
a commercially available kit, according to the manufac-
turer’s instructions (PureLink RNA Mini Kit, Invitrogen).
The RNA concentration was determined by a spectro-
photometer at 260 nm and subsequently transcribed into
cDNA using the Superscript VILO cDNA synthesis kit
(Invitrogen). Real-time RT-PCR was performed as de-
scribed previously [34] using the following forward and
reverse primer sequences: Col1a1, 5′-CACCCTCAA
GAGCCTGAGTC-3′and 5′-GTTCGGGCTGATGTAC
CAGT-3′; Col2a1, 5′-GCCAAGACCTGAAACTCTGC-
3′ and 5′-GCCATAGCTGAAGTGGAAGC-3′; Col3a1,
5′-ACCAAAAGGTGATGCTGGAC-3′ and 5′-GACCTCGTGCTCCAGTTAGC-3′; Col4a1, 5′-AAAGGGAGA
AAGAGGCTTGC-3′ and 5′-CCTTTGTACCGTTGCA
TCCT-3′; Col5a1, 5′-GGTCCCTGACACACCTCAGT-




TG-3′; TGFβ1, 5′- TGAGTGGCTGTCTTTTGACG-3′
and 5′- TCTCTGTGGAGCTGAAGCAA-3′. Gene ex-
pression was quantified using a cycle threshold (CT)
method, whereby a ΔCT was calculated by subtracting
the 18S CT from the gene CT. The relative gene expres-
sion was then calculated using the expression 2−ΔCT.
Statistical analyses
Data were analysed with the GraphPad Prism software.
Statistical significance was determined using a two-way
analysis of variance (ANOVA; for comparison of treat-
ment and group), with significance set at P < 0.05. A
Tukey post hoc multiple comparison test was used where
appropriate to determine significance between groups. For
fatigue data comparing multiple time points, a two-way
repeated measures ANOVA was used. Values are pre-
sented as mean ± SEM.
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